Q1 2027 Anupam Rasayan India Ltd Earnings Call Transcript
Key Points
- Consolidated total income grew 36% year-on-year to INR668 crores, with EBITDA up 35% to INR175 crores and margins maintained at 26%.
- Commercialized Ethyl Trifluoroacetate (ETFA) using flow chemistry, becoming the first company globally to do so, which strengthens its fluorination chemistry expertise and offers a potential $0.5 billion market opportunity.
- Signed a Letter of Intent with BASQUEVOLT for a potential long-term supply deal worth approximately USD300 million over 10 years, adding to a cumulative signed LOI pipeline of roughly INR18,000 crores.
- Jayhawk Fine Chemicals acquisition is contributing 20-22% of consolidated revenue with robust EBITDA margins of 19-20%, and provides a strategic US manufacturing base for high-value markets like semiconductors and defense.
- The proposed Bliss GVS Pharma acquisition is on track for completion by mid-September, which will create an integrated pharmaceutical platform with a pipeline of 62 molecules and significant headroom for capacity utilization improvement.
- Major CapEx cycle is complete, with no significant capital expenditure required for the existing Anupam platform in the near term, and Jayhawk is unlevered and self-sufficient for its own CapEx needs.
- Consolidated PAT growth was only 6% year-on-year to INR51 crores, impacted by higher depreciation from Jayhawk and increased asset base, with PAT margin at approximately 8%.
- Excluding Jayhawk's contribution, organic revenue growth was single-digit, indicating a tepid Q1 seasonally and slower underlying growth in the existing business.
- The agrochemical segment saw lower contribution due to demand cycle weakness, though management expects stability and recovery.
- Working capital remains a focus area, with only stable performance in Q1 and improvement expected only gradually through FY27.
- The Bliss GVS acquisition involves taking on debt of around INR300 crores and an equity-linked instrument, which could increase financial leverage and dilute earnings if not managed well.
- Management refrained from providing detailed guidance on Bliss GVS's performance and integration, citing regulatory constraints, leaving uncertainty for investors.
(technical difficulty) Q1 FY27 Earnings Conference Call. Before we begin, a brief disclaimer. This conference call may contain forward-looking statements about the company, which are based on beliefs, opinions and expectations of the company as on date of this call. These statements are not guarantee of future performance and involve risks and uncertainties that are difficult to predict.
From the management side, we have with us today Mr. Anand Desai, Managing Director; Mr. Gopal Agrawal, Chief Executive Officer; Mr. Amit Khurana, Chief Financial Officer; and Mr. Vishal Thakkar, Deputy Chief Financial Officer.
(Operator Instructions) Please note that this conference is being recorded.
With this, I would now like to hand over the call to Mr. Anand Desai, Managing Director, for his opening comments. Thank you, and over to you, sir.
Thank you. Good afternoon, and thank you for joining us for our Q1 FY27 earnings call. We are pleased to begin FY27 on a strong
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
